Te Ahumairangi Investment Management Ltd Acquires New Position in DaVita Inc. $DVA

Te Ahumairangi Investment Management Ltd bought a new position in shares of DaVita Inc. (NYSE:DVA) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 42,612 shares of the company’s stock, valued at approximately $9,480,000. DaVita comprises 1.5% of Te Ahumairangi Investment Management Ltd’s holdings, making the stock its 17th largest holding.

Other large investors have also made changes to their positions in the company. Root Financial Partners LLC lifted its holdings in shares of DaVita by 128.0% during the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after purchasing an additional 105 shares in the last quarter. Caitlin John LLC bought a new stake in DaVita in the 4th quarter valued at $34,000. Sankala Group LLC acquired a new position in DaVita in the 4th quarter worth $39,000. Canada Pension Plan Investment Board bought a new position in DaVita during the 2nd quarter worth about $43,000. Finally, Kestra Advisory Services LLC acquired a new stake in shares of DaVita in the 4th quarter valued at about $45,000. Institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on DVA shares. UBS Group lifted their target price on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Barclays boosted their price target on DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 5th. Raymond James Financial set a $220.00 price objective on DaVita in a report on Friday, August 7th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $265.00 target price on shares of DaVita in a report on Wednesday, August 5th. Finally, Truist Financial cut their target price on shares of DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research note on Friday, August 7th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $221.75.

DaVita Stock Up 0.2%

Shares of DVA stock opened at $174.21 on Monday. DaVita Inc. has a 12-month low of $101.00 and a 12-month high of $247.49. The company has a market capitalization of $11.11 billion, a PE ratio of 14.26, a price-to-earnings-growth ratio of 0.58 and a beta of 0.88. The firm has a 50 day moving average price of $214.96 and a two-hundred day moving average price of $182.03.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.50 billion. During the same quarter in the previous year, the business earned $2.95 earnings per share. DaVita’s revenue for the quarter was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, research analysts expect that DaVita Inc. will post 14.57 EPS for the current year.

Insider Buying and Selling

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of DaVita stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.90% of the stock is owned by corporate insiders.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.